| Challenges and opportunities for graduate students in public health during the COVID-19 pandemic K Jenei, C Cassidy-Matthews, P Virk, B Lulie, K Closson Canadian Journal of Public Health 111, 408-409, 2020 | 57 | 2020 |
| Evaluation of the clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada DE Meyers, K Jenei, TM Chisamore, B Gyawali JAMA Internal Medicine 181 (4), 499-508, 2021 | 33 | 2021 |
| Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward K Jenei, Z Aziz, C Booth, B Cappello, F Ceppi, EGE de Vries, A Fojo, ... The Lancet Global Health 10 (12), e1860-e1866, 2022 | 28 | 2022 |
| Regulatory decisions diverge over aducanumab for Alzheimer’s disease MP Lythgoe, K Jenei, V Prasad British Medical Journal 376, 2022 | 23 | 2022 |
| Rethinking representation and diversity in deliberative minipublics D Steel, N Bolduc, K Jenei, M Burgess Journal of Deliberative Democracy 16 (1), 2020 | 20 | 2020 |
| Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study K Jenei, AJN Raymakers, A Bayle, K Berger-Thürmel, A Cherla, K Honda, ... The Lancet Oncology 24 (6), 624-635, 2023 | 18 | 2023 |
| The inclusion of women in global oncology drug trials over the past 20 years K Jenei, DE Meyers, V Prasad JAMA Oncology 7 (10), 1569-1570, 2021 | 17 | 2021 |
| High US drug prices have global implications K Jenei, V Prasad, MP Lythgoe British Medical Journal 376, 2022 | 10 | 2022 |
| Describing sources of uncertainty in cancer drug formulary priority setting across Canada K Jenei, S Peacock, M Burgess, C Mitton Current Oncology 28 (4), 2708-2719, 2021 | 8 | 2021 |
| What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020) K Jenei, A Haslam, T Olivier, M Miljkovíc, V Prasad BMJ open 12 (10), e064458, 2022 | 7 | 2022 |
| Experiences and perspectives of individuals accessing CAR-T cell therapy: a qualitative analysis of online Reddit discussions K Jenei, M Burgess, S Peacock, AJN Raymakers Journal of Cancer Policy 30, 100303, 2021 | 6 | 2021 |
| Early-phase clinical trials and reimbursement submissions to the Pan-Canadian oncology drug review AJN Raymakers, KM Jenei, DA Regier, MM Burgess, SJ Peacock PharmacoEconomics 39 (3), 373-377, 2021 | 6 | 2021 |
| Improving the response to future pandemics requires an improved understanding of the role played by institutions, politics, organization, and governance P Berman, MA Cameron, S Gaurav, G Gotsadze, MZ Hasan, K Jenei, ... PLOS Global Public Health 3 (1), e0001501, 2023 | 5 | 2023 |
| CostPlus and implications for generic imatinib K Jenei, MP Lythgoe, V Prasad The Lancet Regional Health–Americas 13, 2022 | 4 | 2022 |
| Assessment of price and clinical benefit of cancer drugs in Canada, 2011-2020 K Jenei, D Meyers, B Gyawali JAMA network open 6 (1), e2253438-e2253438, 2023 | 3 | 2023 |
| The timing of cancer drug approvals in the United States and Europe K Jenei JAMA Network Open 5 (6), e2216191-e2216191, 2022 | 3 | 2022 |
| Globalisation of clinical trials in oncology: a double-edged sword? K Jenei, FY Moraes, B Gyawali BMJ Oncology 2 (1), 2023 | 2 | 2023 |
| Consequences of US FDA approval decisions in high-income countries K Jenei The Lancet Oncology 23 (4), e160, 2022 | 2 | 2022 |
| Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015–2020 K Jenei, A Raymakers, DE Meyers, V Prasad Journal of Cancer Policy 30, 100311, 2021 | 2 | 2021 |
| Grading of recommendations, assessment, development and evaluations concept 7: issues and insights linking guideline recommendations to trustworthy essential medicine lists T Piggott, L Moja, K Jenei, T Kredo, N Skoetz, R Banzi, D Trapani, ... Journal of Clinical Epidemiology 166, 111241, 2024 | 1 | 2024 |
